Report: The Trump Administration Offered “Large Sums” to Secure Exclusive Rights to a Coronavirus Vaccine

Alex Brandon/AP

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

The Trump administration attempted to persuade a German science firm with “large sums of money” to leave Europe and develop a coronavirus vaccine “only for the United States,” according to reporting in a German newspaper Sunday.

It’s a bizarre tale. From Reuters:

Earlier, the Welt am Sonntag German newspaper reported that U.S. President Donald Trump had offered funds to lure CureVac to the United States, and the German government was making counter-offers to tempt it to stay.

There was no comment immediately available from the U.S. embassy in Berlin when contacted by Reuters over the report.

The basics: CureVac, a German biopharmaceutical company, is developing an experimental vaccine for the coronavirus that it hopes to have by June or July, when it would then push for approval on human testing. Earlier this month, Trump, Vice President Mike Pence, and administration and industry leaders met with CureVac’s CEO, Daniel Menichella, to discuss the vaccine. (Menichella was replaced as CureVac CEO by the company’s founder on March 11.)  Die Welt then reported that the United States reached out to broker an exclusive deal on the vaccine, prompting the German government to try to counter.

For its part, CureVac issued a statement on Sunday, saying, “The company rejects current rumors of an acquisition.”

But a spokesperson for the health ministry of Germany confirmed to Reuters there is an ongoing battle.

“The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe,” a Health Ministry spokeswoman said, confirming a quote in the newspaper.

“In this regard, the government is in intensive exchange with the company CureVac,” she added.

MOTHER JONES NEEDS YOUR HELP

We have about a $200,000 funding gap and less than a week to go in our hugely important First $500,000 fundraising campaign. We urgently need your help, and a lot of help, this week so we can pay for the one-of-a-kind journalism you get from us.

Learn more in “Less Dreading, More Doing,” where we lay out this wild moment and how we can keep charging hard for you. And please help if you can: $5, $50, or $500—every gift from every person truly matters right now.

payment methods

MOTHER JONES NEEDS YOUR HELP

We have about a $200,000 funding gap and less than a week to go in our hugely important First $500,000 fundraising campaign. We urgently need your help, and a lot of help, this week so we can pay for the one-of-a-kind journalism you get from us.

Learn more in “Less Dreading, More Doing,” where we lay out this wild moment and how we can keep charging hard for you. And please help if you can: $5, $50, or $500—every gift from every person truly matters right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate